

Addressing Patent Barriers to Vaccine Development & Access

Plenary 3: Growing Developing Country Vaccine Manufacture

Global Vaccine and Immunization Research Forum (GVIRF) 20-22nd March 2018, Bangkok

> Ms Kate Elder Vaccines Policy Advisor, MSF Access Campaign




Outline

- MSF's vaccination work & access challenges
- Competition & DCVMs as critical market stimulator
- MSF research & findings on role of patents in vaccine development
- Strategies for competitors & broader community to address patent barriers
- Legal challenges / opportunities – PCV13 case study
- Conclusion



MSF's vaccination work & access challenges

- 2016: MSF delivered ~6.57 mil doses, >30 countries
- Populations: conflict, natural disasters, no health system
- MSF's main challenges:
 - High prices of newer vaccines
 - Products ill adapted for the conditions of use
 - Shortages or manufacturer refusal to sell




Source: www.msfaccess.org/rightshot2




WE NEED MORE AFFORDABLE VACCINES.





Competition as a critical market stimulator



UNICEF Supply Division 21,28

Source: https://www.msfaccess.org/content/report-right-shotbringing-down-barriers-affordable-and-adapted-vaccines-2nd-ed-2015

MSF research project: what role do patents play in vaccine development (PCV & HPV)?

Methods:

- Literature & patent reviews
- Interviews w/ 15 manufacturers & 5 gov/inter-gov/nonprofit organizations in Brazil, China, India, US

Limitations:

- Restricted to patents
- Patents held by IFPMA companies
- Not a comprehensive patent landscape
- Only covered PCV & HPV vaccines

Legal challenges: the role of patents in PCV & HPV vaccine development



A Fair Shot for Vaccine Affordability

Understanding and addressing the effects of patents on access to newer vaccines

September 2017


MSF Access Dampsign Médecins Sans Frontières Rue de Lausanne 78 CP 118 DH-1211 Geneve 21 Switzenland T + 41 [0] 22 849 84 05
F + 41 [0] 22 849 84 04
access@mst.org | www.mstaccess.org
twiter.com/MSE_access
facebook.com/MSFaccess



September 2017 MSF report shows that:

- There are more and more patents taken out during development of newer vaccines
- Patent applications use overly general language to maximize scope
- This can undermine follow-on development and competition

Patent barriers throughout the vaccine development process



- Many potential unmerited patents (lack of inventive step)
- No transparency
- Little legal and public health experience to overcome patent barriers

Strategies for competitors to address patent barriers

- Prerequisite: comprehensive patent landscape, FTO report (& country-by-country analysis)
- Licensing-in necessary technology
 - Costs; geographic restrictions; other restrictions; obligations (ex. 'grant back' obligations)
- Designing around necessary technology
 - Sometimes impossible; requires highly skilled technical team; time- & resource-consuming
- Challenging patents (eg formal patent oppositions, less formal submissions, other admin or legal procedures)
 - Risky; costly; lengthy & time-consuming

Strategies and recommendations for the collective community to address patent barriers

More transparency in IP landscape (open databases) Improve national / international laws & policies Apply patentability criteria strictly – only new and inventive; no evergreening

Robust access conditions in licensing and other agreements


Challenge unmerited patents Support the use of IP flexibilities, including capacity building and guidance

A role for all companies, governments, UN agencies (WIPO, WHO, UNICEF), donors

Case study: patent barriers to affordable Pneumococcal Conjugate Vaccine (PCV)

- Duopoly market: Pfizer PCV13 & GSK PCV10
- PCV among most expensive vaccines resulting in major access barriers
- No competition yet despite promising pipelines

Graph 1: Price to immunise a child based on lowest price available to Gavi/UNICEF



Sources:

WHO routine immunisation summary tables,⁹ Gavl,¹⁰ UNICEF Supply Division,¹¹ MSF The Right Shot 1# ed.¹²

Pfizer composition patent may block PCV-13 competition, but patent lacks technical merits and can be challenged

Challenging Pfizer's PCV13 composition patent in multiple countries

MSF launches challenge to Pfizer's patent on the pneumonia vaccine in India, to increase access to more affordable versions



Opposition filed by MSF against Pfizer's patent on the pneumonia vaccine at Delhi Patent Office today.

New Delhi/ New York, March 11, 2016 – Médecins Sans Frontières/Doctors Without Borders (MSF) has filed a 'patent opposition' in India to prevent US pharmaceutical company Pfizer from getting a patent on the pneumococcal conjugate vaccine (PCV13), so more affordable versions can become available to developing countries and humanitarian organisations. This is the first time a vaccine (biosimilar) patent has been challenged in India by a medical organisation, with the goal of millions more children being protected against deadly pneumonia.

- **European Patent Office:** patent revoked after being challenged; Pfizer appealing
- US: ongoing post-grant review and inter-partes review to challenge its validity
- India: pre-grant opposition filed by MSF and local producer; patent granted (Aug 2017) & court proceedings continue
- South Korea: pre-grant, postgrant to challenge validity; now at SKr Supreme Court; MSF submitted amicus brief in support of opposition

Conclusions

- Competition critical to sustainable and affordable vaccine access – DCVMs essential to competition
- General lack of consideration / documentation of patent barriers in R&D and resulting competition
- More feedback needed from manufacturers
- Patents increasingly an issue for development of newer vaccines
- Governments should set strict standards of patentability
- Unmerited patents should be challenged
- MSF will continue vaccine IP work for the benefit of our patients and others without access

Feedback on the report welcome



